Connection
Steven Coultrap to Mutation
This is a "connection" page, showing publications Steven Coultrap has written about Mutation.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.229 |
|
|
|
-
Larsen ME, Barker CM, Vargas RS, Coultrap SJ, Bayer KU. The CaMKII D135N mutation blocks kinase activity and reduces GluN2B binding. Mol Pharmacol. 2026 May-Jun; 108(5-6):100127.
Score: 0.108
-
Coultrap SJ, Zaegel V, Bayer KU. CaMKII isoforms differ in their specific requirements for regulation by nitric oxide. FEBS Lett. 2014 Dec 20; 588(24):4672-6.
Score: 0.049
-
Coultrap SJ, Bayer KU. Improving a natural CaMKII inhibitor by random and rational design. PLoS One. 2011; 6(10):e25245.
Score: 0.039
-
Buonarati OR, Cook SG, Goodell DJ, Chalmers NE, Rumian NL, Tullis JE, Restrepo S, Coultrap SJ, Quillinan N, Herson PS, Bayer KU. CaMKII versus DAPK1 Binding to GluN2B in Ischemic Neuronal Cell Death after Resuscitation from Cardiac Arrest. Cell Rep. 2020 01 07; 30(1):1-8.e4.
Score: 0.017
-
Myers JB, Zaegel V, Coultrap SJ, Miller AP, Bayer KU, Reichow SL. The CaMKII holoenzyme structure in activation-competent conformations. Nat Commun. 2017 06 07; 8:15742.
Score: 0.015